WHO Policies

WHO Policies [Link]

WHO. Policy Statement on Xpert MTB-RIF. 2013. [Link]
WHO. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. 2011. [Link]
WHO. Commercial serodiagnostic tests for diagnosis of tuberculosis. 2011. [Link]
WHO. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. 2011. [Link]
WHO. Same-day diagnosis of tuberculosis by microscopy. 2011. [Link]
WHO. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis. 2011. [Link]
WHO. Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis. 2011. [Link]
WHO. Molecular line probe assays for rapid screening of patients at risk of MDR-TB. 2008. [Link]
WHO. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. 2008. [Link]
WHO. Use of liquid medium for culture and DST. 2007. [Link]
WHO. Definition of new smear-positive case and reduction of number of smears. 2007. [Link]